secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-05-22T23:59:59+00:00
Accession:  0001493152-24-020966
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion
--------------------------------------------------------------------------------

- Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.
- First patient dosed in multi-dose portion of Phase I trial, evaluating safety of repeat administrations.
- Company intends to advance Decoy20 into combination studies with a checkpoint inhibitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/0001493152-24-020966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224020966/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-020966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer